Summary
The pharmacokinetics and absolute bioavailability of a new nonselective β-adrenoreceptor blocking agent, carteolol, were investigated after administration of single intravenous and oral doses to eight normal volunteers. Plasma and urine drug concentrations were measured by an HPLC method. The pharmacokinetic parameters after intravenous dosing were obtained by a two-compartment analysis: elimination or β-phase t1/2 4.7±0.3 h; Vc, 0.74±0.101/kg; Vd, 4.05±0.48 l/kg; Cl, 10.13±0.94 ml/min/kg; ClR, 6.56±0.58 ml/min/kg; and ClNR, 3.57±0.40 ml/min/kg. The absolute bioavailability obtained from plasma data was 83.7±8.0%, which was consistent with that derived from analysis of urine of 82.7±4.2%. The amounts excreted unchanged in urine up to 48 h after the intravenous and oral doses were 65.0±1.5% and 53.8±3.2% of the administered doses, respectively. The t1/2 for removal of the drug derived from plasma and urine findings after intravenous and oral dosing were similar, which indicates that the main route of elimination of carteolol is via the kidneys. As the ClR of carteolol exceeded the Cl of creatinine there may be renal tubular secretion of the drug.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chiba S (1977) Differential inotropic-chronotropic action of carteolol. Jpn J Pharmacol 27:585–587
Nakagawa K, Murakami N, Yoshizaki S, Tominaga M, Mori H, Yabuuchi Y, Shintani S (1974) Derivatives of 3,4-dihydrocarbostyril as β-adrenergic blocking agents. J Med Chem 17:529–533
Hashimoto K, Kimura T, Yabuuchi Y (1976) Comparison of newly synthetized beta-adrenergic blockers, OPC-1085 and SQ 111725, with pindolol and propranolol in the blood-perfused canine SA node and papillary muscle preparations. Jpn J Pharmacol 25:504–506
Fitzgerald JD (1969) Perspectives in adrenergic beta-receptor blockade. Clin Pharmacol Ther 10:292–306
Tarkiainen A, Saraste K, Seppälä T, Gordin A, Auvinen J (1981) A controlled study of the antihypertensive effect of carteolol, a new β-adrenergic receptor blocking drug, in combination with hydrochlorthiazide and amiloride. Eur J Clin Pharmacol 19:239–244
Alcocer L, Aspe J, Arce-Gomez E (1980) The antianginal activity of the beta blocker carteolol. Clin Res 28: 153A
Stoll RW, Cavanaugh JH, MacLeod CM (1981) Beta-blocking effect of single oral doses of carteolol. Clin Pharmacol Ther 30:605–610
Morita S, Inuma M, Kido M, Sakuragi S, Kohri H, Nishino H (1977) Metabolic fate of carteolol hydrochloride, (OPC-1085) VIII, a new β-adrenergic blocking agent: Pharmacokinetic studies of carteolol in man. Arzneim Forsch 27:2380–2383
Ishizaki T, Ohnishi A, Sasaki T, Chiba K, Suganuma T, Kushida K (1983) Concentration-effect and effect-time relationships of carteolol. Eur J Clin Pharmacol (in press)
Brown RD, Manno JE (1978) ESTRIP, a BASIC computer program for obtaining initial polyexponential parameter estimates. J Pharm Sci 67:1687–1691
Loo JCK, Riegelman S (1970) Assessment of pharmacokinetic constants from postinfusion blood curves obtained after i.v. infusion. J Pharm Sci 59:53–55
Gibaldi M (1969) Estimation of the pharmacokinetic parameters of the two-compartment open model from post-infusion plasma concentration data. J Pharm Sci 58:1133–1135
Riegelman S, Loo JCK, Rowland M (1968) Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment. J Pharm Sci 57:117–123
Boxenbaum HG, Riegelman S, Elashoff RM (1974) Statistical estimation in pharmacokinetics. J Pharmacokinet Biopharm 2:123–148
Conolly ME, Kersting F, Dollery CT (1976) The clinical pharmacology of beta-adrenoceptor-blocking drugs. Prog Cardiovasc Dis 19:203–234
Frishman W (1979) Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 1. Pharmacodynamic and pharmacokinetic properties. Am Heart J 97:663–670
Frishman W (1981) β-Adrenoceptor antagonists: New drugs and new indications. N Engl J Med 305:500–506
Ishizaki T, Hirayama H, Tawara K, Nakaya H, Sato M, Sato K (1980) Pharmacokinetics and pharmacodynamics in young normal and elderly hypertensive subjects: A study using sotalol as a model drug. J Pharmacol Exp Ther 212:173–181
Triggs EJ, Nation RL (1975) Pharmacokinetics in the aged: A review. J Pharmacokinet Biopharm 3:387–418
Crooks J, O'Malley K, Stevenson IH (1976) Pharmacokinetics in the elderly. Clin Pharmacokinet 1:280–296
Jusko WJ (1978) Role of tobacco smoking in pharmacokinetics. J Pharmacokinet Biopharm 6:7–39
Vestal RE, Wood AJJ, Branch RA, Shand DG, Wilkinson GR (1976) Effects of age and cigarette smoking on propranolol disposition. Clin Pharmacol Ther 26:8–15
Meier J (1982) Pharmacokinetic comparison of pindolol with other beta-adrenoceptor-blocking agents. Am Heart J 104:364–373
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ishizaki, T., Ohnishi, A., Sasaki, T. et al. Pharmacokinetics and absolute bioavailability of carteolol, a new β-adrenergic receptor blocking agent. Eur J Clin Pharmacol 25, 95–101 (1983). https://doi.org/10.1007/BF00544023
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00544023